The Role of Recombinant Protein Technology in the Development and Global Impact of Gardasil: Addressing HPV-Induced Cancers and Advancing Vaccine Strategies
DOI:
https://doi.org/10.61173/dmyamx40Keywords:
HPV Vaccine, Gardasil, Recombinant pro-tein, Immunity, Vaccine hesitancyAbstract
HPV (Human Papilloma Virus) is classified into low or high-risk genotype. It is responsible for nearly 5% of all human cancers in both sexes worldwide; certain high-risk genotypes can cause cervical cancer in women. Gardasil vaccine is designed to prevent HPV infections in people aged 9 to 45. By utilizing virus-like particles (VLPs), which are non-infectious mimics of the virus, the vaccine triggers a robust immune response without the risk of causing the disease. One of the major advantages of using recombinant proteins in vaccines like Gardasil is that they are highly immunogenic and allow for precise targeting of specific viral strains. Researchers have proven that Gardasil is safe and effective in clinical trials, although such data is limited for pregnant women. Promoting Gardasil globally will require continued efforts to raise awareness about the vaccine’s benefits, address vaccine hesitancy, and ensure equitable access, particularly in regions where HPV-related cancers are most prevalent.
References
Schools should utilize educational interventions such as Papilloma Virus Vaccination. Viruses, 2021, 13(6): 1091. pamphlets, movies, workshops, and consulting sessions to [2] Hirth Jacqueline. Disparities in HPV vaccination rates and educate students on HPV vaccination [16]. This approach HPV prevalence in the United States: a review of the literature.
is highly recommended because of its significant effec- Human Vaccines & Immunotherapeutics. 2018, 15(1):146-155. tiveness in improving vaccine acceptance [17]. [3] Soliman Monica, Oredein Ololade, Dass Crispin R. Update Additionally, governments can consider providing fi- on Safety and Efficacy of HPV Vaccines: Focus on Gardasil. nancial incentives or free vaccination to low-income International Journal of Molecular and Cellular Medicine. 2021, households, lowering the barrier of vaccination. Free vac- 10(2):101-113. cination was proven to be the most effective measure in [4] Griffiths Anthony J.F. Recombinant DNA Technology | Dean&Francis Yuhe Xue Definition, Steps, Examples, & Invention. In: Encyclopædia [12] HPV Vaccination [Internet]. Cancer.gov. 2022 [cited 2024
Britannica. 2018. https://www.britannica.com/science/ Oct 29]. Available from: https://progressreport.cancer.gov/ recombinant-DNA-technology prevention/hpv_immunization#jump-links-field-healthy-people- [5] Burgess Richard R, Deutscher Murray P. Guide to Protein 2030-target
Purification. Academic Press, Cop; 2009. [13] Eric Adjei Boakye, Nair Mrudula, Abouelella Dina K, [6] Carlos Juan, Herrera Teobaldo, Rudiwilai Samakoses, Christine L.M. Joseph, Gerend Mary A, Subramaniam Divya Reina John H, Punnee Pitisuttithum, Àngels Ulied, et al. Ten- S, et al. Trends in Reasons for Human Papillomavirus Vaccine Year Follow-up of 9-Valent Human Papillomavirus Vaccine: Hesitancy: 2010–2020. Pediatrics [Internet]. 2023 May 23 [cited
Immunogenicity, Effectiveness, and Safety. Pediatrics. 2023, Sep 2023 Dec 8];151(6). Available from: https://publications.aap.org/ 5;152(4). pediatrics/article-abstract/151/6/e2022060410/191309/Trends- [7] Akuzum Begum, Kim Sinae, Nguyen Tam Thanh, et al. L1 in-Reasons-for-Human-Papillomavirus-Vaccine?redirectedFrom Recombinant Proteins of HPV Tested for Antibody Forming =fulltext?autologincheck=redirected Using Sera of HPV Quadrivalent Vaccine. Immune Network. [14] M oha nty Sa lini, Le a de r A my E, G ibe a u Em i l y, 2018, 18(3). Johnson Caroline. Using Facebook to reach adolescents for [8] Setiawan Didik, Nurulita Nunuk Aries, Khoirunnisa Sudewi human papillomavirus (HPV) vaccination. Vaccine. 2018, Mukaromah, Postma Maarten J. The clinical effectiveness of Sep;36(40):5955–61. one-dose vaccination with an HPV vaccine: A meta-analysis of [15] Cunningham-Erves Jennifer, Hull Pamela C, Wilkins 902,368 vaccinated women. PLoS ONE. 2024, 19(1):1-18. Consuelo H., Edwards Kathryn M., Davis Megan, Jones Jessica, [9] Min Kyung-Jin, Kwon Sang-Hoon, Kim Kidong, et al. et al. Healthcare Providers’ Practice protocols, strategies, and Clinical guideline for 9-valent HPV vaccine: Korean Society Needed Tools to Address Parental HPV Vaccine hesitancy: an of Gynecologic Oncology Guideline. Journal of Gynecologic Exploratory Study. Human Vaccines & Immunotherapeutics.
Oncology. 2019, 30(2). 2022, Nov 14;18(6). [10] Narducci Andrea, Einarson Adrienne, Bozzo Pina. Human [16] Aguolu Obianuju G., Malik Amyn A., Ahmed Noureen,
papillomavirus vaccine and pregnancy. PubMed. 2012, 58(3). Omer Saad B. Overcoming Vaccine Hesitancy for Future [11] Goldstone Stephen E. Human papillomavirus (HPV) COVID-19 and HIV Vaccines: Lessons from Measles and HPV
vaccines in adults: Learnings from long-term follow-up of Vaccines. Current HIV/AIDS Reports. 2022, Sep 17;19(5):328– quadrivalent HPV vaccine clinical trials. Human Vaccines & 43.
Immunotherapeutics. 2023, 19(1).
Downloads
Published
Issue
Section
License
Copyright (c) 2025 by the authors.
This work is licensed under a Creative Commons Attribution 4.0 International License.
